Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Energenesis Biomedical CoTPE:6657 -5.56%64 PS Ratio is 390.23 as of Jul. 17, 2026, which is 31% below its 10-year median of 564.70. GuruFocus rates TPE:6657 with a GF Score™ of 64/100 and a GF Value™ of NT$51.46 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Energenesis Biomedical Co ranks worse than 92.69% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Energenesis Biomedical Co's share price is NT$33.95.
Energenesis Biomedical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.09. Hence, Energenesis Biomedical Co's PS Ratio for today is 390.23.
Good Sign:
Energenesis Biomedical Co Ltd stock PS Ratio (=405.75) is close to 3-year low of 396.55.
The historical rank and industry rank for Energenesis Biomedical Co's PS Ratio or its related term are showing as below:
TPE:6657'
s PS Ratio Range Over the Past 10 Years
Min: 347.31 Med: 564.7 Max: 1967.6
Current: 390.23
During the past 11 years, Energenesis Biomedical Co's highest PS Ratio was 1967.60. The lowest was 347.31. And the median was 564.70.
TPE:6657's PS Ratio is ranked worse than 92.69% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs TPE:6657: 390.23
Energenesis Biomedical Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Energenesis Biomedical Co was -14.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -10.40% per year.
During the past 11 years, Energenesis Biomedical Co's highest 3-Year average Revenue per Share Growth Rate was 6.40% per year. The lowest was -34.20% per year. And the median was -6.75% per year.
Back to Basics: PS Ratio
Energenesis Biomedical Co (TPE:6657) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Energenesis Biomedical Co PS Ratio Related Terms
Energenesis Biomedical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Energenesis Biomedical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Energenesis Biomedical Co's Share Price of today is NT$33.95. Energenesis Biomedical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Energenesis Biomedical Co (TPE:6657) has a PS Ratio of 390.23 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Energenesis Biomedical Co and its competitors. This is 31% below median its historical median of 564.70. Over the past decade, Energenesis Biomedical Co's PS Ratio has ranged from 347.31 to 1,967.60. According to the industry distribution chart, Energenesis Biomedical Co ranks #862 out of 930 companies in the Biotechnology industry, placing it in the top 92.7%.
Is Energenesis Biomedical Co's PS Ratio too high?
Energenesis Biomedical Co's current PS Ratio of 390.23 is 31% below median its 10-year median of 564.70. Over the past 10 years, this metric has ranged from a low of 347.31 to a high of 1,967.60. The Biotechnology industry median PS Ratio is 9.30. Energenesis Biomedical Co's value of 390.23 is 4096% above this industry median. Based on the distribution chart, Energenesis Biomedical Co ranks #862 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Energenesis Biomedical Co has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #862 out of 930 companies for PS Ratio. This places Energenesis Biomedical Co in the lower half of its industry. The industry median PS Ratio is 9.30. Energenesis Biomedical Co's value of 390.23 is 4096% above this benchmark. Historically, Energenesis Biomedical Co's own PS Ratio has ranged from 347.31 to 1,967.60 over the past decade. While the company's 10-year median is 564.70 vs. the industry median of 9.30, Energenesis Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Energenesis Biomedical Co's current PS Ratio of 390.23 is 4096% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current PS Ratio is 390.23, which is 31% below median its own 10-year median of 564.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.46, compared to a current price of NT$33.95 — trading 34% below its estimated fair value. The current PS Ratio is 390.23, which is 31% below median its 10-year median of 564.70 and 4096% above the Biotechnology industry median of 9.30. Energenesis Biomedical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current PS Ratio is 390.23 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$33.95 is trading 34% below its estimated GF Value™ of NT$51.46.
GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.
Key valuation signals for TPE:6657:
PS Ratio: 390.23 (31% below median its 10-year median of 564.70)
GF Value™: NT$51.46 vs. price of NT$33.95 (34% below fair value)
Industry Position: 4096% above the Biotechnology median (#862 of 930)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
64GF Score
Get the complete analysis for TPE:6657
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
